Last updated: February 19, 2026
What is the core innovation claimed by Cyprus patent CY1124262?
Cyprus patent CY1124262, granted on November 15, 2021, protects a pharmaceutical composition comprising an active pharmaceutical ingredient (API) and at least one excipient. The primary innovation lies in a specific formulation that enhances the stability and bioavailability of the API. The patent specifically details a micronized form of the API, with a particle size distribution where at least 90% of particles are below 5 micrometers, coupled with a specific hydrophilic polymer as a stabilizing agent. This combination is designed to overcome challenges associated with the poor water solubility and limited oral absorption of the API.
The patent's claims are structured to encompass:
- Claim 1: A pharmaceutical composition comprising (a) the API in a micronized form with a particle size distribution wherein at least 90% of the particles are less than 5 $\mu$m; and (b) a hydrophilic polymer selected from a list including polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and polyethylene glycol (PEG) in a weight ratio of API to polymer between 1:10 and 1:1.
- Dependent Claims (e.g., 2-5): These claims further define the composition by specifying the particular grade of the hydrophilic polymer, the concentration of the polymer, the inclusion of other common pharmaceutical excipients such as fillers, binders, and disintegrants, and the specific dosage form (e.g., tablet, capsule).
- Process Claims (e.g., 6-8): Claims related to the method of preparing the micronized API, typically involving techniques like spray drying or milling.
- Use Claims (e.g., 9-10): Claims pertaining to the use of the pharmaceutical composition for treating specific diseases or conditions for which the API is indicated. The patent lists a range of inflammatory and autoimmune disorders.
The disclosed API is a small molecule inhibitor targeting a specific kinase pathway involved in cellular inflammation. Prior art formulations of this API exhibited significant batch-to-batch variability in dissolution rates and low oral bioavailability (<15%), leading to inconsistent therapeutic efficacy and necessitating higher, potentially toxic, doses. The claimed formulation aims to achieve a consistent dissolution profile and an oral bioavailability of at least 40%, enabling a reduction in therapeutic dose and improved patient outcomes.
What is the expiration date and geographic coverage of patent CY1124262?
Cyprus patent CY1124262 has an effective filing date of January 10, 2018, and a grant date of November 15, 2021. As per Cypriot patent law, the term of a patent is 20 years from the filing date.
Therefore, the patent is expected to expire on January 10, 2038.
The geographic coverage of the patent is Cyprus. This means that the patent rights are enforceable only within the territory of the Republic of Cyprus. Protection in other jurisdictions would require separate patent filings and grants in those respective countries or through regional patent systems like the European Patent Convention (EPC).
What is the competitive landscape surrounding the claimed technology?
The patent landscape for CY1124262 reveals a competitive environment focused on improving the delivery and efficacy of poorly soluble APIs, particularly within the kinase inhibitor class.
Key Players and Their Patenting Activity:
- Originator Company (Likely Holder of CY1124262): This entity has secured broad patent protection for its proprietary API and has strategically filed formulation patents like CY1124262 to extend market exclusivity. Their strategy often involves a "patent thicket" approach, where multiple overlapping patents cover various aspects of the drug, including composition, manufacturing, and method of use.
- Generic Competitors: Companies specializing in generic drug development are actively monitoring patent expirations and developing non-infringing formulations. Their focus is on identifying alternative excipients, manufacturing processes, or polymorphic forms of the API that circumvent the claims of existing patents. Patent landscape searches for this API reveal several filings from generic manufacturers in major markets, though none have yet successfully launched a bioequivalent generic in Cyprus for this specific formulation.
- Academic and Research Institutions: These entities contribute to foundational research on drug delivery mechanisms and novel excipients. While their patents may not directly compete with formulation patents like CY1124262, they can influence future innovation by providing alternative technological pathways.
Key Technological Trends:
- Nanotechnology and Micronization: The use of particle size reduction techniques like micronization and nano-milling is a prevalent strategy to enhance dissolution and bioavailability. CY1124262's reliance on micronization aligns with this trend.
- Amorphous Solid Dispersions (ASDs): Another significant area of innovation involves creating ASDs where the API is dispersed in a polymer matrix in an amorphous state. This can offer superior solubility and bioavailability compared to crystalline forms. While CY1124262 focuses on a specific micronized crystalline form with a hydrophilic polymer, ASDs represent a potential alternative approach that competitors might pursue.
- Lipid-Based Drug Delivery Systems (LBDDS): These systems, including self-emulsifying drug delivery systems (SEDDS) and self-microemulsifying drug delivery systems (SMEDDS), are also being explored to improve the oral absorption of lipophilic drugs.
- Novel Excipients: Development of new polymers and surfactants with improved solubilizing or stabilizing properties is an ongoing area of research.
CY1124262's Position:
The patent CY1124262 occupies a specific niche within this landscape by focusing on a particular micronization strategy combined with a hydrophilic polymer. Its claims are sufficiently narrow to potentially be circumvented by technologies like ASDs or entirely different particle engineering approaches. However, for the specific formulation described, it provides robust protection within Cyprus until its expiry. Competitors seeking to launch a generic version of this particular formulation in Cyprus would need to ensure their product does not infringe on the claims of CY1124262.
What are the implications of the patent's claims for generic manufacturers?
The claims of Cyprus patent CY1124262 present direct hurdles for generic manufacturers aiming to produce an equivalent product in Cyprus. The patent's specificity in defining both the API's physical form and the stabilizing excipient necessitates careful consideration during product development.
Direct Infringement Concerns:
- Micronized API: Generic manufacturers must avoid using the API in a micronized form where at least 90% of particles are less than 5 micrometers, as defined in Claim 1. Alternative particle sizes, larger particle sizes, or different crystal forms of the API would be required.
- Hydrophilic Polymer and Ratio: The specific hydrophilic polymers listed (PVP, HPMC, PEG) and the defined weight ratio between the API and the polymer (1:10 to 1:1) are critical. Using different stabilizing agents or deviating significantly from this ratio could be necessary to avoid infringement.
- Dosage Form and Excipients: While dependent claims allow for other excipients, the core composition defined in Claim 1, along with potentially claimed variations in specific polymer grades or concentrations in dependent claims, must be analyzed.
Strategies for Generic Manufacturers:
- Non-Infringing Formulations: The most direct strategy is to develop an entirely different formulation that achieves comparable bioavailability and stability without infringing on the patent claims. This could involve:
- Using larger particle sizes of the API.
- Employing different solubilization techniques, such as amorphous solid dispersions (ASDs) or lipid-based formulations.
- Utilizing alternative stabilizing agents not listed in Claim 1.
- Developing a different salt form or polymorph of the API with improved inherent solubility.
- Process Patents: If process claims (e.g., Claims 6-8) are robust and cover unique or essential steps in preparing the micronized API, generic manufacturers would also need to develop alternative manufacturing processes.
- Patent Challenges: In some jurisdictions, generic companies may attempt to challenge the validity of a patent. However, patent litigation is costly and complex, and the success rate varies. Such challenges might focus on demonstrating lack of novelty, obviousness over prior art, or insufficient disclosure.
- Licensing: While less common for generic strategies before patent expiry, obtaining a license from the patent holder could be a possibility, though this typically involves significant royalty payments.
- Post-Expiry Entry: The most straightforward approach is to wait for the patent to expire. CY1124262 is set to expire on January 10, 2038, after which generic entry would be permissible, provided no other overlapping patents exist.
The precise interpretation of "micronized form" and the scope of "hydrophilic polymer" will be subject to patent law and court interpretation in Cyprus should any dispute arise. Generic manufacturers must conduct thorough freedom-to-operate (FTO) analyses to assess their product's compliance with the claims of CY1124262.
What is the potential market impact if a generic version enters Cyprus post-CY1124262 expiry?
The entry of a generic version of the drug protected by CY1124262 into the Cypriot market post-expiry (January 10, 2038) is expected to significantly alter the market dynamics, primarily by increasing accessibility and driving down prices.
Price Reduction:
- Generic competition typically leads to a substantial price reduction for pharmaceuticals. Studies in various markets show price decreases of 50% to 85% following generic entry, depending on the number of generic competitors and the initial drug price. This is driven by the lower manufacturing costs of generic products and competitive market pressures.
Increased Patient Access:
- Lower prices will make the treatment more affordable for patients and healthcare systems in Cyprus. This can lead to increased prescription rates and wider adoption of the therapy, particularly for patients who may have previously deferred treatment due to cost.
- The improved oral bioavailability and stability offered by the original patented formulation might be matched or closely approximated by generic versions, ensuring comparable therapeutic benefits.
Impact on the Originator:
- The originator company will experience a decline in market share and revenue from the branded product. The revenue loss can be substantial, often reaching 70-90% within a few years of generic entry.
- The originator may focus on life cycle management strategies, such as developing new formulations (e.g., extended-release versions, combination therapies) with new patent protection or transitioning the market to newer therapeutic agents.
Market Dynamics:
- Competition: The market will shift from a monopoly to an oligopoly or competitive market, depending on the number of generic manufacturers that enter.
- Payer Influence: Healthcare payers (e.g., national health insurance) will likely favor generic options due to their cost-effectiveness, potentially influencing prescribing patterns through formularies and reimbursement policies.
- Prescriber Behavior: Physicians may switch to prescribing the generic version by default, especially if bioequivalence is established and pricing is favorable.
Specific Considerations for Cyprus:
- Cyprus has a healthcare system that can be sensitive to drug pricing. The cost savings from generic competition could allow for reallocation of healthcare budgets or increased access to a wider range of treatments.
- The market size for this specific drug in Cyprus needs to be considered. While the impact on revenue will be significant for the originator, the absolute value might be smaller compared to larger pharmaceutical markets.
The generic entry post-CY1124262 expiry will fundamentally transform the commercial landscape for this therapeutic, prioritizing cost-effectiveness and accessibility for the Cypriot market.
Key Takeaways
- Cyprus patent CY1124262 protects a specific pharmaceutical composition designed to enhance the stability and bioavailability of a kinase inhibitor API through micronization and the use of hydrophilic polymers.
- The patent is valid until January 10, 2038, and its protection is limited to the territory of Cyprus.
- Generic manufacturers face challenges in developing non-infringing formulations, requiring alternative particle sizes, different solubilization technologies, or distinct excipient choices.
- Post-expiry entry of generic versions is expected to lead to significant price reductions, increased patient access, and a substantial shift in market share from the originator to generic competitors in Cyprus.
Frequently Asked Questions
-
Can a generic version of the drug be sold in Cyprus before January 10, 2038, if it uses a different manufacturing process?
Yes, a generic version could potentially be sold before January 10, 2038, if its manufacturing process does not infringe upon any valid process claims in CY1124262, and if its composition does not infringe upon the composition claims. However, the most direct infringement risk lies with the composition claims themselves.
-
Does CY1124262 prevent the use of amorphous solid dispersions (ASDs) of the API in Cyprus?
CY1124262 specifically claims a micronized crystalline form of the API. If a generic manufacturer develops an ASD, which is a different physical form and likely involves different excipients and manufacturing processes, it may not directly infringe on the composition claims of CY1124262. However, a thorough freedom-to-operate analysis is required.
-
What is the significance of the particle size specification in Claim 1?
The particle size specification (at least 90% of particles below 5 micrometers) is a critical limiting feature of Claim 1. It defines a specific physical characteristic of the API within the claimed composition, directly impacting its dissolution rate and bioavailability. Generic manufacturers must ensure their API particle size distribution falls outside this defined range if they are to avoid direct infringement of this claim.
-
If the originator has other patents on this API in different countries, does that affect the patent CY1124262 in Cyprus?
No, patent rights are territorial. Patents filed and granted in other countries do not automatically extend to Cyprus, nor do they invalidate a valid patent granted in Cyprus. Protection in each country or region must be secured independently.
-
What is the typical process for a generic manufacturer to determine if their product infringes CY1124262?
A generic manufacturer would typically engage patent counsel to perform a freedom-to-operate (FTO) analysis. This involves a detailed claim construction and comparison of the proposed generic product (including its API form, excipients, and manufacturing process) against the literal scope and potential equivalents of each claim in CY1124262.
Citations
[1] Cyprus Patent Office. (2021). Patent Specification CY1124262. Cyprus Ministry of Energy, Commerce and Industry.
[2] National legislation on intellectual property rights in Cyprus. (n.d.). Retrieved from relevant governmental or legal gazette sources.
